Qsemble Capital Management LP Has $202,000 Stock Position in Cencora, Inc. (NYSE:COR)

Qsemble Capital Management LP lowered its position in shares of Cencora, Inc. (NYSE:COR) by 89.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 895 shares of the company’s stock after selling 7,793 shares during the quarter. Qsemble Capital Management LP’s holdings in Cencora were worth $202,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. purchased a new stake in shares of Cencora during the fourth quarter worth $4,212,508,000. Price T Rowe Associates Inc. MD bought a new position in shares of Cencora in the 1st quarter worth $2,183,619,000. JPMorgan Chase & Co. bought a new stake in Cencora during the first quarter worth about $1,199,695,000. Boston Partners bought a new position in Cencora during the first quarter valued at approximately $1,001,269,000. Finally, Capital Research Global Investors purchased a new position in Cencora in the 1st quarter worth $650,424,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling

In related news, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at $63,323,746.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the transaction, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the sale, the insider now owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. The disclosure for this sale can be found here. Insiders have sold a total of 4,450,399 shares of company stock valued at $1,070,392,799 over the last quarter. Corporate insiders own 15.80% of the company’s stock.

Cencora Stock Performance

Shares of Cencora stock opened at $239.88 on Friday. The firm’s 50 day moving average is $233.92 and its two-hundred day moving average is $233.26. Cencora, Inc. has a 52 week low of $175.50 and a 52 week high of $247.66. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The firm has a market capitalization of $47.27 billion, a P/E ratio of 26.25, a P/E/G ratio of 1.55 and a beta of 0.44.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The firm had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. During the same period in the prior year, the firm posted $2.92 EPS. The firm’s revenue was up 10.8% compared to the same quarter last year. Research analysts forecast that Cencora, Inc. will post 13.63 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were issued a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 0.85%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Leerink Partners restated an “outperform” rating and issued a $275.00 price objective on shares of Cencora in a research report on Thursday, June 27th. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Wells Fargo & Company raised their price target on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. StockNews.com upgraded Cencora from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, Robert W. Baird decreased their price target on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Cencora has an average rating of “Moderate Buy” and an average target price of $258.13.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.